Current status of stem cell transplantation for multiple myeloma

被引：1
作者：
Gertz M.A. [1 ]
Lacy M.Q. [1 ]
Dispenzieri A. [1 ]
Hayman S. [1 ]
机构：
[1] Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905
来源：
Current Treatment Options in Oncology | 2005年 / 6卷 / 3期
关键词：
Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Bortezomib; Zoledronic Acid;
D O I：
10.1007/s11864-005-0006-1
中图分类号：
学科分类号：
摘要：
Stem cell transplantation for myeloma has become a standard of care for newly diagnosed patients. Current evidence favors tandem transplants for those patients not achieving a complete or very good partial response (<90%) after the first transplant. Transplantation is safe and has been shown to prolong survival even in patients 65 to 70 years of age. Whether the new agents thalidomide, lenalidomide, and bortezomib will have an impact on the survival advantage of stem cell transplantation is unknown. Copyright © 2005 by Current Science Inc.
引用
收藏
页码：229 / 240
页数：11
相关论文
共 55 条
[1]  
Gulbrandsen N., Wisloff F., Brinch L., Et al., Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support, Med. Oncol., 18, pp. 65-77, (2001)
[2]  
Badros A., Barlogie B., Siegel E., Et al., Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years, Br. J. Haematol., 114, pp. 600-607, (2001)
[3]  
Badros A., Barlogie B., Siegel E., Et al., Results of autologous stem cell transplant in multiple myeloma patients with renal failure, Br. J. Haematol., 114, pp. 822-829, (2001)
[4]  
Moreau P., Misbahi R., Milpied N., Et al., Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma, Leukemia, 16, pp. 1838-1843, (2002)
[5]  
Le Blanc R., Montminy-Metivier S., Belanger R., Et al., Allogeneic transplantation for multiple myeloma: Further evidence for a GVHD-associated graft-versus-myeloma effect, Bone Marrow Transplant., 28, pp. 841-848, (2001)
[6]  
Imrie K., Esmail R., Meyer R.M., Et al., The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: A practice guideline of the Cancer Care Ontario Practice Guidelines Initiative, Ann. Intern. Med., 136, pp. 619-629, (2002)
[7]  
Attal M., Harousseau J.L., Randomized trial experience of the Intergroupe Francophone du Myelome, Semin. Hematol., 38, pp. 226-230, (2001)
[8]  
Child J.A., Morgan G.J., Davies F.E., Et al., High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma, N. Engl. J. Med., 348, pp. 1875-1883, (2003)
[9]  
Vesole D.H., Simic A., Lazarus H.M., Controversy in multiple myeloma transplants: Tandem autotransplants and miniallografts, Bone Marrow Transplant., 28, pp. 725-735, (2001)
[10]  
Lenhoff S., Hjorth M., Holmberg E., Et al., Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study, Blood, 65, pp. 7-11, (2000)
123456